The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.
Y. Ung
No relevant relationships to disclose
C. Gu
No relevant relationships to disclose
K. Cline
No relevant relationships to disclose
A. Sun
No relevant relationships to disclose
R. M. MacRae
No relevant relationships to disclose
J. R. Wright
No relevant relationships to disclose
E. Yu
No relevant relationships to disclose
L. Ehrlich
No relevant relationships to disclose
K. Y. Gulenchyn
No relevant relationships to disclose
H. Shulman
No relevant relationships to disclose
I. S. Dayes
No relevant relationships to disclose
S. K. Dhesy-Thind
No relevant relationships to disclose
G. E. Darling
No relevant relationships to disclose
N. B. Leighl
No relevant relationships to disclose
W. K. Evans
No relevant relationships to disclose
J. A. Julian
No relevant relationships to disclose
M. N. Levine
No relevant relationships to disclose